Rhenman & Partners Asset Management’s TG Therapeutics TGTX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$275K	Buy	+5,000	New	+$205K	0.03%	99
2026 Q1	–	Sell	-73,250	Closed	-$2.18M	–	102
2025 Q4	$2.18M	Sell	73,250 -19,750	-21%	-$645K	0.2%	86
2025 Q3	$3.36M	Sell	93,000 -22,000	-19%	-$725K	0.37%	70
2025 Q2	$4.14M	Sell	115,000 -62,500	-35%	-$2.33M	0.52%	56
2025 Q1	$7M	Sell	177,500 -85,000	-32%	-$2.86M	0.8%	39
2024 Q4	$7.9M	Buy	262,500 +91,000	+53%	+$2.61M	0.81%	46
2024 Q3	$4.01M	Sell	171,500 -42,000	-20%	-$917K	0.33%	72
2024 Q2	$3.8M	Buy	213,500 +90,000	+73%	+$1.44M	0.36%	64
2024 Q1	$1.88M	Sell	123,500 -36,500	-23%	-$581K	0.18%	79
2023 Q4	$2.73M	Hold	160,000	–	–	0.27%	69
2023 Q3	$1.34M	Buy	160,000 +105,000	+191%	+$1.46M	0.14%	79
2023 Q2	$1.37M	Buy	+55,000	New	+$1.42M	0.14%	79

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Rhenman & Partners Asset Management's TGTX Position: Q2 2026 in Review

Rhenman & Partners Asset Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 5,000 shares worth $275K. The stake represents 0.03% of the portfolio and ranks #99 among its holdings. This is a return to the name: Rhenman & Partners Asset Management previously reported a position in TGTX as recently as Q4 2025.

Rhenman & Partners Asset Management first reported a position in TGTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $7.9M in Q4 2024. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Rhenman & Partners Asset Management held 5,000 shares of TG Therapeutics worth $275K as of Q2 2026.
TG Therapeutics was a new Rhenman & Partners Asset Management position in Q2 2026.
TG Therapeutics made up 0.03% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #99 holding.
Rhenman & Partners Asset Management first reported a position in TG Therapeutics in Q2 2023 and has held it in 12 quarters since.
Rhenman & Partners Asset Management's TG Therapeutics position peaked at $7.9M in Q4 2024.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.